These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 23633485)

  • 21. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.
    Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE
    Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
    Smirnova T; Zhou ZN; Flinn RJ; Wyckoff J; Boimel PJ; Pozzuto M; Coniglio SJ; Backer JM; Bresnick AR; Condeelis JS; Hynes NE; Segall JE
    Oncogene; 2012 Feb; 31(6):706-15. PubMed ID: 21725367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation.
    Williams MM; Vaught DB; Joly MM; Hicks DJ; Sanchez V; Owens P; Rahman B; Elion DL; Balko JM; Cook RS
    Breast Cancer Res; 2017 Sep; 19(1):105. PubMed ID: 28886748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
    Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
    Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.
    Zhang H; Zhang L; He Y; Jiang D; Sun J; Luo Q; Liang H; Wang T; Li F; Tang Y; Yang Z; Liu W; Rao Y; Chen C
    Cancer Lett; 2024 Aug; 598():217112. PubMed ID: 38986734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
    Morrison MM; Hutchinson K; Williams MM; Stanford JC; Balko JM; Young C; Kuba MG; Sánchez V; Williams AJ; Hicks DJ; Arteaga CL; Prat A; Perou CM; Earp HS; Massarweh S; Cook RS
    J Clin Invest; 2013 Oct; 123(10):4329-43. PubMed ID: 23999432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
    Liu P; Cheng H; Santiago S; Raeder M; Zhang F; Isabella A; Yang J; Semaan DJ; Chen C; Fox EA; Gray NS; Monahan J; Schlegel R; Beroukhim R; Mills GB; Zhao JJ
    Nat Med; 2011 Aug; 17(9):1116-20. PubMed ID: 21822287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
    Stern DF
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
    Brady SW; Zhang J; Seok D; Wang H; Yu D
    Mol Cancer Ther; 2014 Jan; 13(1):60-70. PubMed ID: 24249715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation.
    Raghuram N; Temel EI; Kawamata T; Kozma KJ; Loch AJ; Wang W; Adams JR; Muller WJ; Egan SE
    Breast Cancer Res; 2024 May; 26(1):86. PubMed ID: 38807216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
    Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
    J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
    Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
    Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse ER+/PIK3CA
    Stratikopoulos EE; Kiess N; Szabolcs M; Pegno S; Kakit C; Wu X; Poulikakos PI; Cheung P; Schmidt H; Parsons R
    Oncogene; 2019 Jan; 38(1):47-59. PubMed ID: 30076411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.
    Simond AM; Rao T; Zuo D; Zhao JJ; Muller WJ
    Oncogene; 2017 Oct; 36(43):6059-6066. PubMed ID: 28783168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.
    Vaught DB; Stanford JC; Young C; Hicks DJ; Wheeler F; Rinehart C; Sánchez V; Koland J; Muller WJ; Arteaga CL; Cook RS
    Cancer Res; 2012 May; 72(10):2672-82. PubMed ID: 22461506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.